//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
Excited that our paper describing a phase 1 trial of ducabtagene autloeucel, a rapidly manufactured anti-BCMA CAR-T in r/r multiple myeloma, was published. #ScienceTranslationalMedicine Huge thanks to all my co-authors, the teams at @danafarber.bsky.social and Novartis, and to our patients.
15d
Durcabtagene autoleucel, a rapidly manufactured BCMA-directed CAR T cell therapy, was safe and efficacious in relapsed/refractory multiple myeloma.
www.science.org
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma
Adam Sperling, MD, PhD